Results
Thirty-eight patients were
included. All patients were heavily pre-treated with a median of five
prior regimens. .....
The VEGF serum level decreased during treatment in
all patients. A low pre-treatment VEGF level was predictive to response.
Conclusions
Single agent bevacizumab has
activity in ovarian cancer patients. Pre-treatment serum VEGF seems to
have predictive value.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.